Raising a Series A in biotech.
A biotech Series A usually funds IND-enabling work and the first trial in people. Here is the bar and who usually leads.
Biotech
Biotech investors fund data, not traction. Each round buys the next experiment that removes a risk: a preclinical result, an IND, a clinical readout. Grants and licensing deals often matter as much as equity.
What Series A investors expect in biotech
Series A diligence is scientific and deep. Expect experts to test each of these.
A data package ready for the clinic
- Toxicology and pharmacology studies done or underway
- A manufacturing process that can make clinical supply
- Pre-IND feedback from the regulator, if you have it
A first trial design
- A Phase 1 plan with clear safety endpoints
- Early efficacy signals the trial can capture
- Sites, a contract research partner and a budget
A team built for development
- A chief medical or development leader in place
- Regulatory and manufacturing expertise in-house or contracted
- A board with drug development experience
How the round comes together
Biotech Series A rounds are led by specialist life science funds, often as a syndicate.
- 1 · A specialist fund leads
- 2 · A syndicate co-leads
- 3 · Strategics join
Multi-stage VCs
Often leads
Life science venture funds lead most Series A rounds, often with co-leads.
Corporate VCs
Often follows
Pharma venture arms invest to track assets that fit their pipelines.
Pre-seed & seed funds
Often follows
Seed investors usually take their pro-rata.
Family offices
Sometimes
Families focused on a disease area co-invest beside specialists.
Grants & non-dilutive
Sometimes
Disease foundations and public programs can fund parts of a trial.
A priced round, often tranched
Series A is priced equity, sometimes funded in tranches tied to an IND or first-patient milestone. Expect board seats for the leads and standard protections. Read the milestone language closely.
The slides investors read first
Asset
What it is and the patients it serves.
Data package
Preclinical results and regulator feedback.
Trial plan
Phase 1 design, endpoints and timing.
CMC
How you will make clinical supply.
The plan
Cash to the next readout and what it proves.
Questions founders ask
Do I need an IND before Series A?
No. Many Series A rounds fund the work that leads to the IND and the first trial. Investors want a credible plan, budget and timeline to get there.
Why do biotech investors syndicate?
Drug development is costly and risky. Several specialist funds share the round so there is enough capital, and enough insider support, to reach the next readout.
Sources
Sources: FDA guidance on IND applications and clinical phases; federal research grant program guidance; university technology transfer practice; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.